Targeting receptor tyrosine kinases in gastric cancer

Table 1 Phase III trials of targeted Receptor tyrosine kinases in advenced gastric cancer

Clinical trial	Line of treatment	RTK inhibitor	Chemotherapy	Status
ToGA	First	Trastuzumab	FP or XP	Completed
AVAGAST	First	Bevacizumab	XP	Completed
EXPAND	First	Cetuximab	XP	Completed
REAL-3	First	Panitumumab	EOX	Completed
LoGIG	First	Lapatinib	OX	Ongoing
TYTAN	Second	Lapatinib	T	Ongoing

ToGA: Trastuzumab for gastric cancer; AVAGAST: Avastin in gastric cancer; EXPAND: Erbitux in combination with xeloda and cisplatin in advanced esophago-gastric cancer; REAL-3: Randomized ECF for advanced and locally advanced esophagogastric cancer 3; LoGIG: Lapatinib optimization study in ErbB2 (HER-2) positive gastric cancer; TYTAN: Lapatinib (Tykerb) with paclitaxel (Taxol) in Asian ErbB2+ (HER+) gastric cancer study; F: 5-fluorouracil; P: Cisplatin; X: Capecitabine; E: Epirubicin; T: Paclitaxel.